CN117757795A - 微小rna及其使用方法 - Google Patents

微小rna及其使用方法 Download PDF

Info

Publication number
CN117757795A
CN117757795A CN202410174429.6A CN202410174429A CN117757795A CN 117757795 A CN117757795 A CN 117757795A CN 202410174429 A CN202410174429 A CN 202410174429A CN 117757795 A CN117757795 A CN 117757795A
Authority
CN
China
Prior art keywords
mir
nucleic acid
mirna
expression
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410174429.6A
Other languages
English (en)
Chinese (zh)
Inventor
A·D·萨利赫
C·万韦斯
Z·陈
H·程
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirecule Inc
US Department of Health and Human Services
Original Assignee
Mirecule Inc
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirecule Inc, US Department of Health and Human Services filed Critical Mirecule Inc
Publication of CN117757795A publication Critical patent/CN117757795A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202410174429.6A 2016-03-07 2017-03-07 微小rna及其使用方法 Pending CN117757795A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662304844P 2016-03-07 2016-03-07
US62/304,844 2016-03-07
PCT/US2017/021178 WO2017156015A2 (en) 2016-03-07 2017-03-07 Micrornas and methods of their use
CN201780027750.XA CN109312341B (zh) 2016-03-07 2017-03-07 微小rna及其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780027750.XA Division CN109312341B (zh) 2016-03-07 2017-03-07 微小rna及其使用方法

Publications (1)

Publication Number Publication Date
CN117757795A true CN117757795A (zh) 2024-03-26

Family

ID=58361152

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202410174429.6A Pending CN117757795A (zh) 2016-03-07 2017-03-07 微小rna及其使用方法
CN201780027750.XA Active CN109312341B (zh) 2016-03-07 2017-03-07 微小rna及其使用方法
CN202410174426.2A Pending CN117757794A (zh) 2016-03-07 2017-03-07 微小rna及其使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201780027750.XA Active CN109312341B (zh) 2016-03-07 2017-03-07 微小rna及其使用方法
CN202410174426.2A Pending CN117757794A (zh) 2016-03-07 2017-03-07 微小rna及其使用方法

Country Status (7)

Country Link
US (2) US11655469B2 (enExample)
EP (1) EP3426781B1 (enExample)
JP (1) JP2019512489A (enExample)
CN (3) CN117757795A (enExample)
DK (1) DK3426781T3 (enExample)
ES (1) ES2986046T3 (enExample)
WO (1) WO2017156015A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3492607A3 (en) * 2017-11-30 2019-08-14 Università Degli Studi Di Torino Urinary mirnas for the in vitro diagnosis of bladder cancer
WO2020227604A1 (en) * 2019-05-08 2020-11-12 Nova Southeastern University Regulation of nucleotide excision repair (ner) by microrna for treatment of breast cancer
US20220296629A1 (en) * 2019-06-03 2022-09-22 Carmel Haifa University Economic Corporation Ltd. Human head and neck cancer treatment
CN111235274A (zh) * 2020-01-18 2020-06-05 山西医科大学第一医院 喉鳞癌血清外泌体标志物筛选方法和外泌体来源miR-941应用
KR20230023612A (ko) * 2020-04-02 2023-02-17 마이레큘, 인크. 조작된 올리고뉴클레오티드를 사용한 표적화된 억제
CN112007043B (zh) * 2020-08-24 2021-07-20 谢琦 抗结直肠癌的药物或组合物
WO2022056454A2 (en) * 2020-09-14 2022-03-17 President And Fellows Of Harvard College Methods and compositions for treating hpv-positive cancers
CN112294960B (zh) * 2020-10-30 2022-02-08 浙江大学 微小分子RNA-30b-5p作为靶分子的用途
CN112359115B (zh) * 2020-11-30 2022-08-30 河北仁博科技有限公司 与肿瘤细胞顺铂耐药性相关的miR-517a-3p及其应用
CN112481273B (zh) * 2020-12-29 2023-11-24 南通大学附属医院 结直肠癌抑癌基因及其启动子区高dna甲基化的验证方法
EP4124656A1 (en) * 2021-07-26 2023-02-01 Martin-Luther-Universität Halle-Wittenberg Pd-l1 micrornas
CN113528669A (zh) * 2021-08-19 2021-10-22 柳州市工人医院 一种利用Small RNA测序技术揭示miRNA对肝癌作用机制的方法
US20250101525A1 (en) * 2022-01-21 2025-03-27 Griffith University Biomarkers and uses therefor
CN114574596B (zh) * 2022-03-11 2023-06-23 浙江省农业科学院 SNPs分子标记g.43851G＞A及其在湖羊分子标记辅助育种中的应用
CN115161321B (zh) * 2022-06-24 2023-04-18 天津市农业科学院 ssc-miR-30c-3p在制备抗PDCoV增殖药物中的应用
CA3261027A1 (en) * 2022-07-10 2024-01-18 Precigen, Inc. POLYCISTRONIC MIARN CONSTRUCTIONS FOR IMMUNE CHECKPOINT INHIBITION
CN120731090A (zh) * 2022-12-28 2025-09-30 学校法人自治医科大学 腹膜种植抑制剂、腹膜种植抑制方法、腹膜种植预防方法以及腹膜种植治疗方法
WO2024163383A2 (en) * 2023-01-30 2024-08-08 Academia Sinica Treating spinal muscular atrophy (sma) by modulating mir34 and use of mir34 as a predictive biomarker of sma
EP4417709A1 (en) * 2023-02-14 2024-08-21 Gemeinnützige Salzburger Landeskliniken Betriebsges.mbH Mirna-based diagnostic assay for the detection of a risk to develop skin tumors against the background of severe skin lesions
WO2024197262A1 (en) * 2023-03-23 2024-09-26 Purdue Research Foundation Fully modified mir-34a and related conjugates, compositions and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012107724A1 (en) * 2011-02-09 2012-08-16 Ucl Business Plc Mir-30 for use in the modulation of angiogenesis
US20120308647A1 (en) * 2010-02-16 2012-12-06 University Of Miami Use of mir-30e to treat vascular lesions
US20150018539A1 (en) * 2013-01-26 2015-01-15 Mirimus, Inc. Modified mirna as a scaffold for shrna
US20150313932A1 (en) * 2014-04-14 2015-11-05 Dana-Farber Cancer Institute, Inc. Composition and method for treating a hematological malignancy

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
DK1504126T3 (da) 2002-05-03 2014-06-10 Univ Duke Fremgangsmåde til regulering af genekspression
WO2005017145A1 (ja) 2003-08-13 2005-02-24 Japan Biological Informatics Consortium 機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法
US7626014B2 (en) 2004-04-27 2009-12-01 Alnylam Pharmaceuticals Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
AU2005323437B2 (en) 2004-04-30 2011-10-06 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a C5-modified pyrimidine
CA2572151A1 (en) 2004-06-30 2006-08-24 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a non-phosphate backbone linkage
WO2006093526A2 (en) 2004-07-21 2006-09-08 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a modified or non-natural nucleobase
CA2583375C (en) * 2004-09-02 2013-01-15 Yale University Regulation of oncogenes by micrornas
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
EP1904111A4 (en) 2005-06-03 2009-08-19 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR REDUCING MICRORNA EXPRESSION FOR THE TREATMENT OF NEOPLASIA
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
EP2796554A3 (en) 2005-09-12 2014-12-10 The Ohio State University Research Foundation Compositions for use in treating BCL2-associated cancers
US8603991B2 (en) 2005-11-18 2013-12-10 Gradalis, Inc. Individualized cancer therapy
AU2006326517B2 (en) 2005-12-12 2013-02-21 The University Of North Carolina At Chapel Hill MicroRNAs that regulate muscle cell proliferation and differentiation
CN103642900B (zh) 2006-01-05 2016-04-13 俄亥俄州立大学研究基金会 用于诊断和治疗实体癌的基于微小rna的方法和组合物
WO2007143752A2 (en) 2006-06-09 2007-12-13 The Regents Of The University Of California Targets in breast cancer for prognosis or therapy
WO2007149521A2 (en) 2006-06-20 2007-12-27 The Johns Hopkins University Nucleotide motifs providing localization elements and methods of use
WO2008011431A2 (en) * 2006-07-17 2008-01-24 Sirna Therapeutics Inc. Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina)
WO2008069940A2 (en) 2006-12-06 2008-06-12 Albert Einstein College Of Medicine Of Yeshiva University Multi-microrna methods and compositions
CN101622349A (zh) 2006-12-08 2010-01-06 奥斯瑞根公司 作为治疗性干预靶标的miR-21调节的基因和途径
EP2111408A4 (en) 2007-01-17 2010-02-03 Univ Johns Hopkins COMPOSITIONS AND METHODS OF microRNA FOR THE TREATMENT OF NEOPLASIA
CN101808649B (zh) 2007-07-31 2014-05-21 得克萨斯系统大学董事会 控制肌球蛋白表达和肌纤维身份的微小rna
US20090148535A1 (en) * 2007-12-06 2009-06-11 Minerva Biotechnologies Corporation Method for treating cancer using interference rna
EP2306978A2 (en) 2008-06-06 2011-04-13 Mirna Therapeutics, Inc. Compositions for the in vivo delivery of rnai agents
JP2010094122A (ja) 2008-06-12 2010-04-30 Keio Gijuku バイオマーカーとしてのマイクロｒｎａを用いた頭頸部腫瘍の診断・治療選択
US8729041B2 (en) 2008-12-03 2014-05-20 The Johns Hopkins University Compositions and methods for treating hepatic neoplasia
US20120148664A1 (en) 2009-06-08 2012-06-14 Miragen Therapeutics Chemical modifications motifs for mirna inhibitors and mimetics
US8796238B2 (en) 2009-09-17 2014-08-05 Sigma-Aldrich Co. Llc Short RNA mimetics
CA2799403C (en) * 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
CN105969773A (zh) * 2011-02-03 2016-09-28 米尔纳医疗股份有限公司 Mir-124的合成模拟物
JP2014506791A (ja) 2011-02-03 2014-03-20 マーナ セラピューティクス インコーポレイテッド ｍｉＲ−３４の合成模倣体
US9428749B2 (en) 2011-10-06 2016-08-30 The Board Of Regents, The University Of Texas System Control of whole body energy homeostasis by microRNA regulation
TWI516267B (zh) 2011-11-07 2016-01-11 臺北榮民總醫院 抑制癌症或腫瘤細胞之類癌幹細胞特性及抗化學及放射治療特性的醫藥組合物
JP6587142B2 (ja) * 2013-02-15 2019-10-09 国立大学法人 東京医科歯科大学 マイクロｒｎａからなるがん治療剤
RU2707540C2 (ru) * 2014-04-25 2019-11-27 Чилдрен'С Медикал Сентр Корпорэйшн Композиции и способы для лечения гемоглобинопатий

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120308647A1 (en) * 2010-02-16 2012-12-06 University Of Miami Use of mir-30e to treat vascular lesions
WO2012107724A1 (en) * 2011-02-09 2012-08-16 Ucl Business Plc Mir-30 for use in the modulation of angiogenesis
US20150018539A1 (en) * 2013-01-26 2015-01-15 Mirimus, Inc. Modified mirna as a scaffold for shrna
US20150313932A1 (en) * 2014-04-14 2015-11-05 Dana-Farber Cancer Institute, Inc. Composition and method for treating a hematological malignancy

Also Published As

Publication number Publication date
DK3426781T3 (da) 2024-09-30
ES2986046T3 (es) 2024-11-08
CN109312341A (zh) 2019-02-05
JP2019512489A (ja) 2019-05-16
US20190284554A1 (en) 2019-09-19
US20230295631A1 (en) 2023-09-21
WO2017156015A3 (en) 2017-10-19
CN117757794A (zh) 2024-03-26
US11655469B2 (en) 2023-05-23
WO2017156015A2 (en) 2017-09-14
EP3426781B1 (en) 2024-06-26
CN109312341B (zh) 2024-02-27
EP3426781A2 (en) 2019-01-16

Similar Documents

Publication Publication Date Title
CN109312341B (zh) 微小rna及其使用方法
ES2727334T3 (es) Métodos y ensayos basados en microARN para el osteosarcoma
US20210292764A1 (en) Lung cancer diagnostics and therapeutics with mir-660
JP2013523126A (ja) ｍｉＲ−１５５によるミスマッチ修復およびゲノム安定性の調節に関連する材料および方法
WO2012006181A2 (en) Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
JP5931897B2 (ja) マイクロｒｎａ−２１、ミスマッチ修復および結腸直腸癌に関連する物質および方法
US10030269B2 (en) Biomarkers, methods, and compositions for inhibiting a multi-cancer mesenchymal transition mechanism
JP6895175B2 (ja) エクソソーム分泌阻害剤
CN111088357B (zh) 针对escc的肿瘤标志物及其应用
WO2019199733A1 (en) Compositions and methods for treating cancer
EP2852669B1 (en) Therapeutic micro rna targets in chronic pulmonary diseases
CN115074444A (zh) miR-5189-3p在头颈部鳞癌诊疗中的应用
EP4360657A1 (en) Mir-326 for the treatment of cancer
WO2024110458A1 (en) Lnc-znf30-3 as cancer biomarker and therapeutic target
WO2022081693A1 (en) Compositions and methods targeting circ2082 for the treatment of cancer
WO2017005957A1 (es) Determinación de la metilación y niveles de un miarn en respuesta a un compuesto antitumoral basado en platino
JP2025534768A (ja) 特発性肺線維症のための低分子ｒｎａベースの予後シグネチャ及び治療組成物
Chiadini Study of the interactions between CD99, immunologic microenvironment and microRNAs and their prognostic significance in human osteosarcoma
TW202108763A (zh) 用於治療ipf及pf-ild之病毒載體及核酸
US20150216893A1 (en) Methods and compositions for inhibiting a multi-cancer mesenchymal transition mechanism
US20170088836A1 (en) Treatment and prevention of adrenocortical carcinoma
An et al. Circular RNA circBCBM1 promotes breast cancer brain metastasis by modulating
CN111471679A (zh) 干预eif4h剪接亚型的寡聚核苷酸及其应用
WO2013122918A1 (en) Methods and compositions for inhibiting a multi-cancer mesenchymal transition mechanism

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20240326

WD01 Invention patent application deemed withdrawn after publication